Replimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001737953/000110465926108243/tm2625488d1_8k.htm
Stocks · News reference
Replimune Receives FDA Accelerated Approval For TUDRIQEVTM In Combination With Nivolumab For Treatment Of Adults With Unresectable Advanced Cutaneous Melanoma
Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Replimune Group, Inc. (REPL)
Filed: 2026-09-16 AccNo: 0001104659-26-108243 Size: 215 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
-SEC Filing